Projected Out-of-Pocket Savings of the Medicare Part D $2 Drug List Model.
作者信息
Hernandez Inmaculada, Gabriel Nico, Pathak Yuvraj, Hansen Ryan N, Sullivan Sean D, Fendrick A Mark
机构信息
Division of Clinical Pharmacy, University of California, San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla.
West Health Policy Center, Washington, DC.
出版信息
JAMA. 2025 May 13;333(18):1634-1635. doi: 10.1001/jama.2025.2028.
Abstract
摘要
相似文献
1
Projected Out-of-Pocket Savings of the Medicare Part D $2 Drug List Model.医疗保险D部分2美元药品清单模式的预计自付费用节省情况。
JAMA. 2025 May 13;333(18):1634-1635. doi: 10.1001/jama.2025.2028.
2
Out-of-Pocket Prescription Drug Savings for Medicare Beneficiaries with Asthma and COPD Under the Inflation Reduction Act.《降低通胀法案》下哮喘和慢性阻塞性肺疾病医疗保险受益人的自付处方药节省费用情况
J Gen Intern Med. 2025 Apr;40(5):1141-1149. doi: 10.1007/s11606-024-09063-4. Epub 2024 Oct 4.
3
Effects of Part D Senior Savings Model on healthcare costs among the Medicare population.D部分老年人储蓄模式对医疗保险人群医疗费用的影响。
J Pharm Health Serv Res. 2025 Sep 12;16(3):rmaf017. doi: 10.1093/jphsr/rmaf017. eCollection 2025 Sep.
4
Changes in Out-of-Pocket Drug Expenditures Among Medicare Beneficiaries With Dementia Under the Inflation Reduction Act: A Simulation Study.《降低通胀法案》下患有痴呆症的医疗保险受益人的自付药品费用变化：一项模拟研究
Value Health. 2025 Apr;28(4):553-561. doi: 10.1016/j.jval.2025.01.008. Epub 2025 Jan 27.
5
Estimated True Out-of-Pocket Cost Changes of the Inflation Reduction Act on Medicare Part D Beneficiaries with Cancer.《降低通胀法案》对患有癌症的医疗保险D部分受益人的估计真实自付费用变化
Value Health. 2025 Jul 15. doi: 10.1016/j.jval.2025.07.003.
6
Calcimimetic Prescriptions in Fee-for-Service Medicare Beneficiaries Undergoing Dialysis.接受透析的按服务收费的医疗保险受益人的拟钙剂处方情况。
JAMA Health Forum. 2025 Apr 4;6(4):e250452. doi: 10.1001/jamahealthforum.2025.0452.
7
Changes in Medicare Part D Plan Designs After the Inflation Reduction Act.《降低通胀法案》出台后医疗保险D部分计划设计的变化。
JAMA Intern Med. 2025 Aug 18. doi: 10.1001/jamainternmed.2025.4003.
8
Fiscal Impact of Expanded Medicare Coverage for GLP-1 Receptor Agonists to Treat Obesity.扩大医疗保险覆盖范围以使用GLP-1受体激动剂治疗肥胖症的财政影响。
JAMA Health Forum. 2025 Apr 4;6(4):e250905. doi: 10.1001/jamahealthforum.2025.0905.
9
Identification of Surgeon Outliers to Improve Cost Efficiency: A Novel Use of the Centers for Medicare and Medicaid Quality Payment Program.识别外科医生中的异常值以提高成本效率：医疗保险和医疗补助服务中心质量支付计划的新用途。
J Arthroplasty. 2024 Oct;39(10):2427-2432. doi: 10.1016/j.arth.2024.05.003. Epub 2024 May 9.
10
The Mark Cuban Cost Plus Drug Company Effect on Urogynecologic Drugs.
Urogynecology (Phila). 2025 Oct 1;31(10):994-997. doi: 10.1097/SPV.0000000000001653.
本文引用的文献
1
Assessing the Effect of the Medicare Part D Redesign.评估医疗保险D部分重新设计的效果。
JAMA. 2025 Feb 25;333(8):663-664. doi: 10.1001/jama.2024.25827.
2
Estimated Savings Under the Medicare High-Value Drug List Model.医疗保险高价值药品清单模式下的预计节省费用。
JAMA Intern Med. 2024 Nov 1;184(11):1390-1392. doi: 10.1001/jamainternmed.2024.4846.
Zotero 插件